A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany

被引：0
|
作者：
Maureen Watt
Charles McCrea
Sukhvinder Johal
John Posnett
Jameel Nazir
机构：
[1] Astellas EMEA,
[2] PAREXEL Access Consulting,undefined
[3] Astellas Pharma Europe Ltd.,undefined
来源：
Infection | 2016年 / 44卷
关键词：
Cost-effectiveness; Budget impact; Fidaxomicin; Vancomycin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：599 / 606
页数：7
相关论文
共 50 条
  • [31] Oral Teicoplanin as an Alternative First-Line Regimen in Clostridium difficile Infection in Elderly Patients: A Case Series
    Benjamin Davido
    Céline Leplay
    Frédérique Bouchand
    Aurélien Dinh
    Maryvonne Villart
    Jean-Laurent Le Quintrec
    Laurent Teillet
    Jérôme Salomon
    Hugues Michelon
    Clinical Drug Investigation, 2017, 37 : 699 - 703
  • [32] Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC
    Chen, Ping
    Li, Yinfeng
    Jing, Xiaomei
    Chen, Jing
    Chen, Shimei
    Yang, Qing
    LUNG CANCER, 2022, 174 : 157 - 164
  • [33] Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma
    Liao, Weiting
    Xu, Huiqiong
    Hutton, David
    Wu, Qiuji
    Yang, Yang
    Feng, Mingyang
    Lei, Wanting
    Bai, Liangliang
    Li, Junying
    Li, Qiu
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [34] A cost-effectiveness and budget impact analysis of apremilast in patients with psoriasis in the Italian setting
    Barbieri, Marco
    Loconsole, F.
    Migliore, A.
    Capri, S.
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (04) : 362 - 370
  • [35] A cost-effectiveness and budget impact analysis of apremilast in patients with psoriatic arthritis in Italy
    Capri, Stefano
    Migliore, A.
    Loconsole, F.
    Barbieri, Marco
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (04) : 353 - 361
  • [36] Cost-Effectiveness Analysis of Panitumumab Compared with Bevacizumab for First-Line Treatment of Patients with Wild-Type RAS Metastatic Colorectal Cancer in Germany
    Frank, M.
    Lange, A.
    Michailov, G.
    Lebioda, A.
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2016, 21 (04): : 203 - 209
  • [37] Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France
    Baro, Emilie
    Galperine, Tatiana
    Denies, Fanette
    Lannoy, Damien
    Lenne, Xavier
    Odou, Pascal
    Guery, Benoit
    Dervaux, Benoit
    PLOS ONE, 2017, 12 (01):
  • [38] First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
    Yang, Liu
    Song, Xiaobing
    Zeng, Wanxian
    Zheng, Zhiwei
    Lin, Wenqiang
    ORPHANET JOURNAL OF RARE DISEASES, 2023, 18 (01)
  • [39] First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
    Liu Yang
    Xiaobing Song
    Wanxian Zeng
    Zhiwei Zheng
    Wenqiang Lin
    Orphanet Journal of Rare Diseases, 18
  • [40] Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysis
    Zhang, Peng-Fei
    Wen, Feng
    Wu, Qiu-Ji
    Li, Qiu
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (14) : 1021 - 1030
12345